Skip to Main Content

Paper Details

Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
J Clin Oncol
25
2021
Author NameAffiliation
Eve LapoubleHospital Group, Institut Curie
Peter F AmbrosSt Anna Children's Cancer Research Institute
Marie BernkopfSt Anna Children's Cancer Research Institute
Ga??lle PierronHospital Group, Institut Curie
Sabine Taschner-MandlSt Anna Children's Cancer Research Institute
Shifra AshRuth Rappaport Children's Hospital
Olivier DelattreINSERM U, Institut Curie
Olivier DelattreInstitut Curie
Olivier DelattreInstitut Curie Genomics of Excellence (ICGex) Platform, Research Center, Institut Curie
Ruth LadensteinSt Anna Children's Hospital, St Anna Children's Cancer Research Institute
Ruth LadensteinMedical University of Vienna
Gudrun SchleiermacherInstitut Curie
Gudrun SchleiermacherINSERM U, Institut Curie
Gudrun SchleiermacherInstitut Curie
  • 1 - 14

Datasets

Release 1.2